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1. General Procedures:  
 
Chromatography: Merck silica gel type 9385 230-400 mesh, TLC: Merck silica gel 60, 
0.25 mm. Components were visualized by UV and potassium permanganate staining. 
Progress and conversion of the reaction were determined by GC-MS (GC, HP6890: MS 
HP5973) with an HP1 or HP5 column (Agilent Technologies, Palo Alto, CA). Mass 
spectra were recorded on an AEI-MS-902 mass spectrometer (EI+) or a LTQ Orbitrap 
XL (ESI+). 1H- and 13C-NMR were recorded on a Varian AMX400 (400 and 100.59 
MHz, respectively) or a Varian VXR300 (300 and 75 MHz, respectively) using CDCl3 as 
solvent. Chemical shift values are reported in ppm with the solvent resonance as the 
internal standard (CHCl3:  7.26 for 1H,  77.0 for 13C). Data are reported as follows: 
chemical shifts, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, br = broad, m 
= multiplet), coupling constants (Hz), and integration. Optical rotations were measured 
on a Schmidt + Haensch polarimeter (Polartronic MH8) with a 10 cm cell (c given in 
g/100 mL). Enantiomeric ratios were determined by HPLC analysis using a Shimadzu 
LC-10ADVP HPLC equipped with a Shimadzu SPD-M10AVP diode array detector or by 
capillary GC analysis (HP 6890, CP-Chiralsil-Dex-CB column (25 m x 0.25 mm) using 
flame ionization detector. 
All reactions were carried out under a nitrogen atmosphere using oven dried glassware 
and using standard Schlenk techniques. Dichloromethane was dried and distilled over 
calcium hydride; THF was dried and distilled over sodium. All copper-salts (CuTC, 
CuBr•SMe2, CuI, CuCl, Cu(OTf)2, CuCN, (CuOTf)2•Tol, Cu(MeCN)4PF6 and 
(CuOTf)2•C6H6) were purchased from Aldrich, and used without further purification. 
Allyl bromides 1a,1 1c,2 1f,1 1i,3 1j,3 1k,3 1l4 and 1m,4 1n, 5 1o,6 were prepared following 
a literature procedure. AllylMgBr (1.0 M in Et2O), AllylMgCl (1.0 M in THF), 
Tetraallyltin, Hoveyda-Grubbs Catalyst 2nd Generation (HG-II), Ligands (R,R)-
Taniaphos (L1) and Tol-BINAP (L10) were purchased from Aldrich. AllylLi was 
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prepared as reported in the literature.7 Phosphoramidite ligands L6 and L9 were 
purchased from Strem Chemicals. Phosphoramidite ligands (L2, L3),8 (L4, L5),9 L7,10 
and L1111 and those used in Table S110 were prepared as reported in the literature. 
Phosphoramidite ligand (S,R,R)-L7 was prepared following the same procedure described 
for (S,S,S)-L7.12 
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2. Screening results and additional information 
 
Table S1. Additional phosphoramidites ligands screened for the copper-catalyzed 

















































(b:l) 45:55, 95:5 e.r. (b:l) 48:52, 93:7 e.r. (b:l) 29:71, 64:36 e.r. (b:l) 52:48, 92:8 e.r.
(b:l) 45:55, 74:26 e.r.
(b:l) 35:63, 50:50 e.r. (b:l) 29:71, 50:50 e.r. (b:l) 12:88, 62:38 e.r. (b:l) 60:40, 95:5 e.r.
(b:l) 48:52, 93:7 e.r.
(b:l) 21:79, 59:41 e.r.(b:l) 51:49, 95:5 e.r.(b:l) 65:35, 95:5 e.r.






















Table S2. Effect of different conditions and influence of copper source on the reaction 
 
entrya Other conditions [Cu] source 2a:3ac 2a, e.r.d 
1 Cu/L 1:2 CuBr•SMe2 66:34 96:4 
2 Reaction carried out at -74 ºC CuBr•SMe2 64:36 95:5 
3 Reaction carried out in TBMEe CuBr•SMe2 24:76 63:37 
4 Reaction carried out in Toluene CuBr•SMe2 54:46 60:40 
5  CuI 68:32 97:3 
6  CuCl 67:33 97:3 
7  Cu(OTf)2 56:44 97:3 
8  (CuOTf)2•Tol 75:25 97:3 
9  Cu(MeCN)4PF6 74:26 97:3 
aConditions: 0.2 mmol of allyl bromide, 1.5 eq of allyl magnesium bromide diluted in CH2Cl2, 0.05 M in CH2Cl2, The substrate 
was added over 5 h. bConversion by GC-MS. All reaction gave full conversion unless noted. cbranched/linear ratios determined 
by GC-MS or 1H NMR spectroscopy. dDetermined by chiral HPLC analysis. eTBME= Methyl tert-butyl ether. 
 
By raising the ligand/copper ratio from 1:1 to 2:1 the regioselectivity slightly decreased 
(b,l=66:34) although the e.r. ratio was maintained (entry 1). Upon raising the temperature 
to -74 ºC (entry 2), conversion of the σ-complex to the π-complex can occur,13 resulting 
in a lower regioselectivity. The choice of dichloromethane as the solvent is key to obtain 
high regio- and enantioselectivity. The use of toluene or ethereal solvents as TBME 
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The same procedure as for 1a was followed.1  [87% yield] 
1H NMR (400 MHz, CDCl3), δ: 7.29 (m, 2H), 6.97 (t, J = 7.3 Hz, 1H), 6.90 (d, J = 8.2 
Hz, 2H), 6.05 (m, 2H), 4.56 (dd, J = 0.9, 4.7 Hz, 2H), 3.99 (dd, J = 0.5, 7.0 Hz, 2H). 13C 
NMR (101 MHz, CDCl3), δ: 158.3, 130.1, 129.5 (2C), 129.2, 121.0, 114.6 (2C), 7.1, 






The same procedure as for 6a was followed.1  [72% yield] 
1H NMR (400 MHz, CDCl3), δ: 7.48 (d, J = 8.3 Hz, 2H), 7.27 (m, 5H), 7.02 (m, 2H), 
5.70 (m, 2H), 4.18 (d, J = 5.0 Hz, 2H), 3.80 (d, J = 6.5 Hz, 2H), 2.43 (s, 3H). 13C NMR 
(101 MHz, CDCl3), δ: 143.5, 139.0, 135.3, 130.4, 129.6, 129.5 (2C), 128.9 (2C), 128.8 






The same procedure as for 6a was followed.1  [67% yield] 
1H NMR (400 MHz, CDCl3), δ: 7.47 (d, J = 8.3 Hz, 2H), 7.41 (d, J = 8.6 Hz, 2H), 7.26 
(d, J = 8.2 Hz, 2H),  6.89 (d, J = 8.5 Hz, 2H), 5.68 (m, 2H), 4.14 (d, J = 6.0 Hz, 2H), 3.79 
S8 
(d, J = 6.7 Hz, 2H), 2.43 (s, 3H). 13C NMR (101 MHz, CDCl3), δ: 143.9, 138.0, 134.9, 






The same procedure as for 6a was followed.1  [77% yield] 
1H NMR (400 MHz, CDCl3), δ: 7.55 (d, J = 8.5 Hz, 2H), 7.25 (m, 4H), 6.91 (t, J = 7.3 
Hz, 1H), 6.76 (d, J = 8.5 Hz, 1H), 5.71 (m, 2H), 4.19 (bs, 2H), 3.81 (d, J = 6.0 Hz, 2H), 
3.40 (s, 3H), 2.41 (s, 3H). 13C NMR (101 MHz, CDCl3), δ: 156.3, 142.8, 137.3, 133.2, 





The same procedure as for 6a was followed.1  [68% yield] 
1H NMR (400 MHz, CDCl3), δ: 7.66 (d, J = 8.1 Hz, 2H), 7.32 (d, J = 7.6 Hz, 2H), 5.84 
(m, 1H), 5.66 (m, 1H), 3.89 (d, J = 7.2 Hz, 2H), 3.64 (d, J = 6.5 Hz, 2H), 2.66 (s, 3H), 
2.43 (s, 3H). 13C NMR (101 MHz, CDCl3), δ: 143.5, 134.3, 130.7, 129.7 (2C), 129.4, 





To a solution of 1-allyl-2-methoxybenzene (2.5 mmol, 374 mg) and 1,4-dibromobutene 
(12.6 mmol, 2.7 g) in dry toluene (20 mL), HG-II catalyst (0.25 mmol, 157 mg) was 
added and the mixture was heated at 80 °C for 10h. The mixture was cooled down to 
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room temperature and the solvent was removed under reduced pressure to yield the crude 
product which was purified by flash chromatography on silica gel, n-pentane/Et2O 98:2. 
[67% yield].1H NMR (400 MHz, CDCl3), δ: 7.81 (dt, J = 1.6, 7.5 Hz, 1H), 7.72 (d, J = 
7.4 Hz, 1H), 7.51 (dt, J = 0.9, 7.5 Hz, 1H), 7.46 (d, J = 8.2 Hz, 1H), 6.55 (m, 1H), 6.34 
(m, 1H), 4.56 (d, J = 7.4 Hz, 2H), 4.43 (s, 3H), 3.99 (d, J = 7.0 Hz, 2H). 13C NMR (101 
MHz, CDCl3), δ: 157.2, 134.5, 129.8, 127.8. 127.6, 127.1, 120.5, 110.4, 55.3, 33.4, 32.7. 
 
4. General procedure for the copper-catalyzed enantioselective allyl-allyl cross 
coupling:  
 
A Schlenk tube equipped with septum and stirring bar was charged with (CuOTf)2•C6H6 
(0.01 mmol, 5 mol%, 2.60 mg) and the appropriate phosphoramidite ligand (0.011 mmol, 
5.5 mol%). Dry dichloromethane (2 mL) was added and the solution was stirred under 
nitrogen atmosphere at room temperature for 20 min and the resulting solution was 
cooled to -80 °C. Then, the corresponding allyl bromide 1 (0.2 mmol) in dichloromethane 
(1 mL) was added. In a separate Schlenk flask, allylMgBr (1.0 M in Et2O, 0.30 mmol, 
300µL, 1.5 eq) was diluted with dichloromethane (combined volume of 1 mL) under 
nitrogen and added dropwise to the reaction mixture over 5 h using a syringe pump. Once 
the addition was complete, the mixture was stirred at -80 °C for 16 h. The reaction was 
quenched with MeOH (1 mL), saturated aqueous NH4Cl solution (2 mL) and the mixture 
was warmed up to room temperature, diluted with dichloromethane and the layers were 
separated. The aqueous layer was extracted with dichloromethane (3 x 5 mL) and the 
combined organic layers were dried with anhydrous Na2SO4, filtered and the solvent was 
evaporated in vacuo. The crude product was purified by flash chromatography on silica 
gel using different mixtures of n-pentane/EtOAc or n-pentane/Et2O as the eluent. 
Note: GC-MS or 1H-NMR analysis was carried out to determine the b:l ratio on a sample 










(-)-(2-Bromo-2-(2-vinylpent-4-enyloxy)benzene) (2a): The title compound was 
prepared from 1a using (R,S,S)-L4 as ligand. Purification by column chromatography 
(SiO2, EtOAc/Pentane 1:99, Rf = 0.7) afforded 2a (71% yield, 77:23 ratio (b:l), 97:3 e.r.) 
as a colorless oil. 1H NMR (400 MHz, CDCl3), δ: 7.53 (dd, J = 1.5, 7.9 Hz, 1H), 7.24 (m, 
1H), 6.84 (m, 2H), 5.84 (m, 2H), 5.12 (m, 4H), 3.96 (m, 2H), 2.68 (m, 1H), 2.48 (m, 1H), 
2.31 (m, 1H). 13C NMR (101 MHz, CDCl3), δ: 155.2, 138.4, 135.9, 133.3, 128.3, 121.8, 
116.7, 116.3, 113.2, 112.3, 71.3, 43.0, 35.5. 
[α]D20 = -17.6 (c = 1.0, CHCl3). 
HRMS (ESI+, m/z): calcd. for C13H15BrO, [M+H+]: 267.0385; found: 267.0379. 
Enantiomeric excess was determined by chiral HPLC analysis, Chiralcel OD-H column, 




(+)-(2-Vinylpent-4-enyloxy)benzene (2b). The title compound was prepared from 1b 
using (S,R,R)-L4 as ligand. Purification by column chromatography (SiO2, 
EtOAc/Pentane 1:99, Rf = 0.7) afforded 2b/3b (89% yield, 70:30 ratio (b:l), 95:5 e.r.) as a 
colorless oil. 1H NMR (400 MHz, CDCl3), δ: 7.28 (m, 2H), 6.93 (m, 3H), 5.80 (m, 2H), 
5.08 (m, 4H), 3.92 (d, J = 6.2 Hz, 2H), 2.63 (m, 1H), 2.41 (m, 1H), 2.21 (m, 1H). 13C 
NMR (101 MHz, CDCl3), δ: 158.9, 138.7, 136.0, 129.4 (2C), 120.6, 116.6, 116.1, 114.6 
(2C), 70.3, 43.0, 35.7. 
[α]D20 = +14 (c = 1.0, CHCl3).  
HRMS (ESI+, m/z): calcd. for C13H17O, [M+H+]: 189.1279; found: 189.1274. 
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Enantiomeric excess was determined by chiral HPLC analysis, Chiralcel OD-H column, 




(+)-((2-Vinylpent-4-enyloxy)methyl)benzene (2c). The title compound was prepared 
from 1c using (S,R,R)-L4 as ligand. Purification by column chromatography (SiO2, 
EtOAc/Pentane 1:99, Rf = 0.8) afforded 2c (76% yield, 82:18 ratio (b:l), 95:5 e.r.) as a 
colorless oil. 1H NMR (400 MHz, CDCl3), δ: 7.34 (m, 5H), 5.76 (m, 2H), 5.06 (m, 4H), 
4.52 (s, 2H), 3.43 (d, J = 6.3 Hz, 2H), 2.46 (m, 1H), 2.31 (m, 1H), 2.13 (m, 1H). 13C 
NMR (101 MHz, CDCl3), δ: 139.5, 138.5, 136.4, 128.3 (2C), 127.5 (2C), 127.4, 116.1, 
115.6, 73.0, 73.0, 43.5, 35.8. 
[α]D20 = +48 (c = 1.0, CHCl3). 
HRMS (ESI+, m/z): calcd. for C14H19O, [M+H+]: 203.1436; found: 203.1430. 
Enantiomeric excess was determined by chiral HPLC analysis, Chiralcel OB-H column, 




(-)-4-Methyl-N-phenyl-N-(2-vinylpent-4-enyl)benzenesulfonamide (2d): The title 
compound was prepared from 1d using (R,S,S)-L4 as ligand. Purification by column 
chromatography (SiO2, EtOAc/Pentane 10:90, Rf = 0.7) afforded 2d/3d (90% yield, 83:17 
ratio (b:l), 96:4 e.r.) as a waxy solid. 1H NMR (400 MHz, CDCl3), δ: 7.43 (d, J = 8.3 Hz, 
2H), 7.29 (m, 3H), 7.22 (d, J = 7.8 Hz, 2H), 7.03 (m, 2H), 5.63 (m, 2H), 5.07-4.90 (m, 
4H), 3.48 (m, 2H), 2.41 (s, 3H), 2.26 (m, 1H), 2.15 (m, 1H), 2.08 (m, 1H). 13C NMR (101 
MHz, CDCl3), δ: 143.3, 139.2, 138.9, 135.6, 135.1, 129.3 (2C), 128.9 (2C), 128.8 (2C), 
127.8, 127.7 (2C), 116.6, 116.5, 54.0, 41.9, 36.3, 21.5.  
[α]D20 = -17 (c = 1.0, CHCl3).  
HRMS (ESI+, m/z): calcd. for C20H24NO2S, [M+H+]: 342.1528; found: 342.1522. 
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Enantiomeric excess was determined by chiral HPLC analysis, Chiralpak AD-H column, 







The title compound was prepared from 1e using (R,S,S)-L4 as ligand. Purification by 
column chromatography (SiO2, EtOAc/Pentane 10:90, Rf = 0.7) afforded 2e/3e (88% 
yield, 82:18 ratio (b:l), 97:3 e.r.) as a waxy solid. 1H NMR (400 MHz, CDCl3), δ: 7.42 (d, 
J = 8.3 Hz, 4H), 7.25 (d, J = 7.9 Hz, 2H), 6.90 (d, J = 9.1 Hz, 2H), 5.61 (m, 2H), 5.08-
4.89 (m, 4H), 3.44 (m, 2H), 2.42 (s, 3H), 2.21 (m, 1H), 2.09 (m, 2H). 13C NMR (101 
MHz, CDCl3), δ: 143.6, 138.7, 138.3, 135.4, 134.7, 132.1 (2C), 130.4 (2C), 129.5 (2C), 
127.6 (2C), 121.6, 116.8, 116.7, 53.8, 41.9, 36.3, 21.5.  
[α]D20 = -14 (c = 1.0, CHCl3). 
HRMS (ESI+, m/z): calcd. for C20H23BrNO2S, [M+H+]: 420.0633; found: 420.0627. 
Enantiomeric excess was determined by chiral HPLC analysis, Chiralpak AD-H column, 





The title compound was prepared from 1f using (R,S,S)-L4 as ligand. Purification by 
column chromatography (SiO2, EtOAc/Pentane 10:90, Rf = 0.7) afforded 2f/3f (90% 
yield, 90:10 ratio (b:l), 94:6 e.r.) as a waxy solid. 1H NMR (400 MHz, CDCl3), δ: 7.56 
(m, 3H), 7.26 (m, 5H), 5.60 (m, 2H), 4.96 (m, 4H), 3.68 (m, 1H), 3.49 (m, 1H), 2.42 (s, 
3H), 2.44-2.20 (m, 1H), 2.16-1.93 (m, 2H). 13C NMR (101 MHz, CDCl3), δ: 143.5, 139.1, 
138.3, 137.9, 136.5, 136.4, 135.8, 135.7, 134.1, 134.0, 133.5, 132.3, 129.7, 129.5, 129.4, 
S13 
129.4, 128.0, 127.9, 127.8, 127.7, 116.6, 116.5, 116.4, 55.0, 54.6, 42.9, 42.9, 42.3, 39.6, 
36.6, 21.6.  
[α]D20 = -23 (c = 1.0, CHCl3). 
HRMS (ESI+, m/z): calcd. for C20H23BrNO2S, [M+H+]: 420.0633; found: 420.0627. 
Enantiomeric excess was determined by chiral HPLC analysis, Chiralpak AD-H column, 





The title compound was prepared from 1g using (S,R,R)-L4 as ligand. Purification by 
column chromatography (SiO2, EtOAc/Pentane 10:90, Rf = 0.6) afforded 2g/3g (87% 
yield, 91:9 ratio (b:l), 97:3 e.r.) as a waxy solid. 1H NMR (400 MHz, CDCl3), δ: 7.50 (d, 
J = 8.1 Hz, 2H), 7.31-7.17 (m, 4H), 6.92 (t, J = 7.6 Hz, 1H), 6.75 (d, J = 8.2 Hz, 1H), 
5.63 (m, 2H), 5.07-4.84 (m, 4H), 3.58 (m, 2H), 3.32 (s, 3H), 2.39 (s, 3H), 2.32 (m, 1H), 
2.18 (m, 1H), 2.04 (m, 1H). 13C NMR (101 MHz, CDCl3), δ: 142.6, 139.5, 137.3, 136.1, 
133.6, 129.6, 128.9, 128.8 (2C), 127.6 (2C), 126.7, 120.5, 116.2, 116.1, 111.5, 54.7, 53.4, 
42.8, 36.3, 21.4.  
[α]D20 = +20 (c = 1.0, CHCl3).  
HRMS (ESI+, m/z): calcd. for C21H26NO3S, [M+H+]: 372.1633; found: 372.1628. 
Enantiomeric excess was determined by chiral HPLC analysis, Chiralpak AS-H column, 




(+)-N-Methyl-4-methyl-N-(2-vinylpent-4-enyl)benzenesulfonamide (2h): The title 
compound was prepared from 1h using (S,R,R)-L4 as ligand. Purification by column 
chromatography (SiO2, EtOAc/Pentane 10:90, Rf = 0.7) afforded 2h/3h (81% yield, 74:26 
S14 
ratio (b:l), 96:4 e.r.) as a waxy solid. 1H NMR (400 MHz, CDCl3), δ: 7.65 (d, J = 8.6 Hz, 
2H), 7.31 (d, J = 7.7 Hz, 2H), 5.75 (m, 1H), 5.61 (m, 1H), 5.02 (m, 4H), 3.01 (dd, J = 7.3, 
13.2 Hz, 1H), 2.83 (dd, J = 7.7, 13.2 Hz, 1H), 2.69 (s, 3H), 2.42 (s, 3H), 2.39 (m, 1H), 
2.26 (m, 1H), 2.08 (m, 1H). 13C NMR (101 MHz, CDCl3), δ: 143.2 (2C), 139.0, 135.8, 
129.6 (2C), 127.4 (2C), 116.6, 116.5, 54.1, 42.1, 36.4, 35.4, 21.5. 
[α]D20 = +5.2 (c = 1.0, CHCl3).  
HRMS (ESI+, m/z): calcd. for  C15H22NO2S, [M+H+]: 280.1371; found: 280.1366. 
Enantiomeric excess was determined by chiral HPLC analysis, Chiralpak AD-H column, 





(+)-N-(But-3-enyl)-4-methyl-N-(2-vinylpent-4-enyl)benzenesulfonamide (2i): The 
title compound was prepared from 1i using (R,S,S)-L4 as ligand. Purification by column 
chromatography (SiO2, EtOAc/Pentane 10:90, Rf = 0.8) afforded 2i/3i (93% yield, 75:25 
ratio (b:l), 96:4 e.r.) as a waxy solid. 1H NMR (400 MHz, CDCl3), δ: 7.68 (d, J = 8.3 Hz, 
2H), 7.28 (d, J = 8.3 Hz, 2H), 5.72 (m, 2H), 5.58 (m, 1H), 5.02 (m, 6H), 3.15 (m, 3H), 
3.00 (m, 1H), 2.42 (s, 3H), 2.42 (m, 1H), 2.25 (m, 3H), 2.04 (m, 1H). 13C NMR (101 
MHz, CDCl3), δ: 143.1, 139.2, 136.9, 135.8, 134.7, 129.6 (2C), 127.2 (2C), 116.9, 116.7, 
116.5, 52.3, 48.2, 42.6, 36.5, 32.8, 21.5.  
[α]D20 = +12 (c = 1.0, CHCl3).  
HRMS (ESI+, m/z): calcd. for C18H26NO2S, [M+H+]: 320.1684; found: 320.1679. 
Enantiomeric excess was determined by chiral HPLC analysis, Chiralpak AD-H column, 




(+)-N-Allyl-4-methyl-N-(2-vinylpent-4-enyl)benzenesulfonamide (2j): The title 
compound was prepared from 1j using (R,S,S)-L4 as ligand. Purification by column 
S15 
chromatography (SiO2, EtOAc/Pentane 10:90, Rf = 0.8) afforded 2j/3j (91% yield, 70:30 
ratio (b:l), 95:5 e.r.) as a waxy solid. 1H NMR (400 MHz, CDCl3), δ: 7.69 (d, J = 8.2 Hz, 
2H), 7.29 (d, J = 8.1 Hz, 2H), 5.71 (m, 1H), 5.55 (m, 2H), 5.27-4.93 (m, 6H), 3.79 (m, 
2H), 3.15 (dd, J = 7.2, 13.8 Hz, 1H), 2.99 (dd, J = 8.1, 13.9 Hz, 1H), 2.44 (m, 1H), 2.42 
(s, 3H), 2.22 (m, 1H), 2.03 (m, 1H). 13C NMR (101 MHz, CDCl3), δ: 143.1, 139.3, 135.9, 
133.0, 129.6 (2C), 127.2 (2C), 127.1, 119.0, 116.6, 116.4, 51.1, 51.0, 42.3, 36.5, 21.5.  
[α]D20 = +3.2 (c = 1.0, CHCl3).  
HRMS (ESI+, m/z): calcd. for C17H24NO2S, [M+H+]: 306.1528; found: 306.1522. 
Enantiomeric excess was determined by chiral HPLC analysis, Chiralpak AS-H column, 




(-)-4-Methyl-N-(prop-2-ynyl)-N-(2-vinylpent-4-enyl)benzenesulfonamide (2k): The 
title compound was prepared from 1k using (S,R,R)-L4 as ligand. Purification by column 
chromatography (SiO2, EtOAc/Pentane 10:90, Rf = 0.8) afforded 2k/3k (86% yield, 37:63 
ratio (b:l), 79:21 e.r.) as a waxy solid. 1H NMR (400 MHz, CDCl3), δ: 7.71 (dd, J = 4.4, 
8.3 Hz, 4H), 7.28 (d, J = 8.0 Hz, 4H), 5.95-5.43 (m, 4H), 5.43-5.24 (m, 1H), 5.22-4.66 
(m, 6H), 4.10 (dd, J = 2.4, 21.6 Hz, 4H), 3.76 (d, J = 6.8 Hz, 2H-linear), 3.19 (dd, J = 6.9, 
13.5 Hz, 1H-branched), 3.09 (dd, J = 8.2, 13.5 Hz, 1H-branched), 2.55-2.43 (m, 1H), 
2.41 (s, 6H), 2.31-2.18 (m, 1H), 2.17-2.03 (m, 5H). 13C NMR (101 MHz, CDCl3), δ: 
143.4, 143.4, 139.0, 137.8, 136.2, 136.1, 135.8, 135.6, 129.4 (4C), 127.7 (4C), 123.7, 
116.8, 116.6, 115.0, 76.7, 76.4, 73.8, 73.5, 49.9, 48.3, 41.9, 36.8, 36.6, 35.4, 33.1, 21.5 
(2C).  
HRMS (ESI+, m/z): calcd. for C17H22NO2S, [M+H+]: 304.1371; found: 304.1366. 
Enantiomeric excess was determined by chiral HPLC analysis, Chiralpak AD-H column, 





(+)-1-Bromo-4-(hexa-1,5-dien-3-yl)benzene (2l): The title compound was prepared 
from 1l using (S,R,R)-L4 as ligand. Purification by column chromatography (SiO2, 
Et2O/Pentane 2:98, Rf = 0.8) afforded 2l/3l (81% yield, 46:54 ratio (b:l), 86:14 e.r.) as a 
colorless oil. 1H NMR (400 MHz, CDCl3), δ: 7.41 (m, 8H), 7.22-7.05 (m, 8H), 6.28 (m, 
2H), 5.96 (m, 2H), 5.69 (m, 1H), 5.03 (m, 6H), 3.36 (m, 1H-branched), 2.59 (m, 1H-
branched), 2.46 (m, 1H-branched), 2.27 (m, 4H-linear). 13C NMR (101 MHz, CDCl3), δ: 
142.6, 140.9, 137.9, 136.7, 136.1, 131.5, 131.5, 131.5, 131.4, 130.9, 129.5, 129.4, 129.0, 
127.5 (2C), 120.5, 116.5, 115.1, 115.0, 114.8, 39.6, 38.8, 33.4, 32.4.  
Enantiomeric excess determined by chiral GC analysis, CP-Chiralsil-Dex-CB column (25 
m x 0.25 mm), initial temp. 50°C, then 10°C /min to 80°C, then 1°C /min to 140°C (hold 
for 5 min), then 10°C /min to 180°C (final temp), retention times (min): 102.3 (minor) 
and 104.3 (major). 
 
(-)-1-(Hexa-1,5-dien-3-yl)-2-methoxybenzene (2m): The title compound was prepared 
from 1m using (R,S,S)-L4 as ligand. Purification by column chromatography (SiO2, 
Et2O/Pentane 10:90, Rf = 0.7) afforded 2m/3m (90% yield, 73:27 ratio (b:l), 95:5 e.r.) as 
a colorless oil. Enantiomeric ratio was determined for cross metathesis product 7m. 1H 
NMR (400 MHz, CDCl3), δ: 7.43 (dd, J= 1.0, 7.6 Hz, 1H), 7.18 (m, 3H), 6.90 (m, 3H), 
6.75 (d, J= 15.5 Hz, 1H), 6.24 (m, 1H), 6.03 (m, 1H), 5.89 (m, 1H), 5.76 (m, 1H), 5.01 
(m, 6H), 3.87 (m, 1H-branched), 3.85 (s, 3H), 3.83 (s, 3H), 2.49 (t, J= 7.2 Hz, 2H-
branched), 2.35 (m, 2H-linear), 2.26 (m, 2H-linear). 13C NMR (101 MHz, CDCl3), δ: 
158.9, 156.3, 141.0, 138.3, 137.1, 132.1, 130.8, 127.9, 127.8, 127.1, 126.8, 126.4, 124.7, 
120.6, 120.5, 115.6, 114.8, 114.2, 110.8, 110.7, 55.4 (2C), 42.1, 38.7, 33.7, 32.9. 
[α]D20 = -7.6 (c = 1.0, CHCl3). 








(+)-(2E,6E)-Diethyl 4-(2-methoxyphenyl)octa-2,6-dienedioate (7m): To a solution of 
2m (0.2 mmol) and ethyl acrylate (0.6 mmol) in dry dichloromethane (2 mL), HG-II 
catalyst (0.01 mmol, 5 mol%) was added and the mixture was heated at reflux for 24h. 
The mixture was cooled down to room temperature and the solvent was removed under 
reduced pressure to yield the crude product which was purified by flash chromatography 
(SiO2, EtOAc/Pentane 10:90, Rf = 0.4) affording 7m (65% yield, 95:5 e.r.) as a colorless 
oil. 1H NMR (400 MHz, CDCl3), δ: 7.21 (dt, J = 1.6, 7.7 Hz, 1H), 7.09 (m, 2H), 6.88 (m, 
3H), 5.81 (m, 2H), 4.16 (m, 4H), 4.06 (q, J = 7.2 Hz, 1H), 3.82 (s, 3H), 2.68 (m, 1H), 
2.37 (m, 1H), 1.26 (m, 6H). 13C NMR (101 MHz, CDCl3), δ: 166.4, 166.3, 156.7, 149.8, 
146.1, 128.1, 128.0, 122.9, 122.3, 121.4, 120.8, 118.8, 60.3, 60.2, 55.4, 40.3, 36.2, 14.2 
(2C).  
[α]D20 = +13.6 (c = 1.0, CHCl3). 
HRMS (ESI+, m/z): calcd. for C19H25O5, [M+H+]: 333.1702; found: 333.1697. 
Enantiomeric excess was determined by chiral HPLC analysis, Chiralpak AD-H column, 
n-heptane/i-PrOH 98:2, 40 °C, 231 nm, retention times (min): 29.6 (major) and 34.5 
(minor). 
 
(+)-4-((S)-Hexa-1,5-dien-3-yl)-2,2-dimethyl-1,3-dioxolane (2n): The title compound 
was prepared from 1n using (S,R,R)-L4 as ligand. Purification by column 
chromatography (SiO2, Et2O/Pentane 1:30, Rf = 0.6) afforded anti-2n (81% yield, 
07:84:15 ratio (bsyn:banti:l)) as a colorless oil. 1H NMR (400 MHz, CDCl3), δ: 5.73 (m, 
2H), 5.08 (m, 4H), 4.09 (c, J = 6.1 Hz, 1H), 3.99 (dd, J = 6.1, 7.9 Hz, 1H), 3.65 (t, J = 7.7 
Hz, 1H), 2.23 (m, 2H), 2.13 (m, 1H), 1.40 (s, 3H), 1.35 (s, 3H). 13C NMR (101 MHz, 
CDCl3), δ: 137.6, 136.2, 117.0, 116.3, 108.8, 77.7, 67.3, 46.8, 35.6, 26.4, 25.4.  
[α]D20 = +12 (c = 1.0, CHCl3). 
S18 
HRMS (ESI+, m/z): calcd. for C11H19O2, [M+H+]: 183.1385; found: 183.1380. 
GC analysis was carried out to determine the bsyn:banti:l ratio. 
 
 
(+)-1-Methoxy-2-(2-vinylpent-4-enyl)benzene (2o): The title compound was prepared 
from 1o using (S,R,R)-L4 as ligand. Purification by column chromatography (SiO2, 
EtOAc/Pentane 2:98, Rf = 0.6) afforded 2o (84% yield, 85:15 ratio (b:l), 91:09 e.r.) as a 
colorless oil. Enantiomeric ratio was determined for cross metathesis product 7o. 1H 
NMR (400 MHz, CDCl3), δ: 7.18 (dt, J = 1.9, 7.9 Hz, 1H), 7.09 (dd, J = 1.6, 7.3 Hz, 1H), 
6.86 (m, 2H), 5.81 (m, 1H), 5.68 (m, 1H), 5.02 (m, 2H), 4.89 (m, 2H), 3.81 (s, 3H), 2.74 
(dd, J = 6.6, 13.3 Hz, 1H), 2.61 (dd, J = 7.7, 13.3 Hz, 1H), 2.48 (sex., J = 7.0 Hz, 1H), 
2.14 (m, 2H). 13C NMR (101 MHz, CDCl3), δ: 157.7, 142.2, 137.2, 130.9, 128.9, 127.0, 
120.1, 115.7, 114.1, 110.2, 55.2, 43.6, 38.8, 35.3.  
[α]D20 = +50 (c = 1.0, CHCl3).  
HRMS (ESI+, m/z): calcd. for C14H19O, [M+H+]: 203.1436; found: 203.1430. 
 
 
(+)-(2E,6E)-Diethyl 4-(2-methoxybenzyl)octa-2,6-dienedioate (7o): To a solution of 2o 
(0.2 mmol) and ethyl acrylate (0.6 mmol) in dry dichloromethane (2 mL), HG-II catalyst 
(0.01 mmol, 5 mol%) was added and the mixture was heated at reflux for 24h. The 
mixture was cooled down to room temperature and the solvent was removed under 
reduced pressure to yield the crude product which was purified by flash chromatography 
(SiO2, EtOAc/Pentane 10:90, Rf = 0.7) affording 7o (65% yield, 91:09 e.r.) as a colorless 
oil. 
1H NMR (400 MHz, CDCl3), δ: 7.19 (dt, J = 1.6, 7.7 Hz, 1H), 7.03 (dd, J = 1.6, 7.3 Hz, 
1H), 6.85 (m, 4H), 5.82 (d, J = 15.8 Hz, 1H), 5.68 (d, J = 15.8 Hz, 1H), 4.16 (m, 4H), 
3.80 (s, 3H), 2.72 (m, 3H), 2.32 (m, 2H), 1.27 (m, 6H). 13C NMR (101 MHz, CDCl3), δ: 
S19 
166.4, 166.3, 157.5, 151.0, 146.2, 130.8, 127.8, 127.2, 123.1, 121.4, 120.3, 110.3, 60.2 
(2C), 55.1, 41.6, 36.2, 35.0, 14.2, 14.2. 
[α]D20 = -16 (c = 1.0, CHCl3).  
HRMS (ESI+, m/z): calcd. for C20H27O5, [M+H+]: 347.1858; found: 347.1853. 
Enantiomeric excess was determined by chiral HPLC analysis, Chiralpak AD-H column, 




(+)-4-Vinyldodec-1-ene (2p): The title compound was prepared from 1p using (R,S,S)-
L4 as ligand. Purification by column chromatography (SiO2, Et2O/Pentane 1:99, Rf = 0.9) 
afforded 2p/3p (84% yield, 88:12 ratio (b:l), 97:3 e.r.) as a colorless oil. Enantiomeric 
ratio was determined for cross metathesis product 7p. 1H NMR (400 MHz, CDCl3), δ: 
5.76 (m, 1H), 5.59 (m, 1H), 4.98 (m, 4H), 2.17-1.94 (m, 3H), 1.26 (m, 14H), 0.89 (t, J = 
7.0 Hz, 3H). 13C NMR (101 MHz, CDCl3), δ: 143.6, 138.0, 116.3, 114.8, 44.5, 40.3, 35.0, 
32.7, 30.5, 30.4, 30.1, 27.9, 23.5, 14.9. 
[α]D20 = +2.0 (c = 1.0, CHCl3). 







(-)-(2E,6E)-Diethyl 4-octylocta-2,6-dienedioate (7p): To a solution of 2p (0.2 mmol) 
and ethyl acrylate (0.6 mmol) in dry dichloromethane (2 mL), HG-II catalyst (0.01 mmol, 
5 mol%) was added and the mixture was heated at reflux for 24h. The mixture was 
cooled down to room temperature and the solvent was removed under reduced pressure to 
yield the crude product which was purified by flash chromatography (SiO2, 
EtOAc/Pentane 10:90, Rf = 0.5) affording 7p (71% yield, 97:3 e.r.) as a colorless oil. 1H 
NMR (400 MHz, CDCl3), δ: 6.84 (dt, J = 7.1, 15.5 Hz, 1H), 6.74 (dd, J = 8.3, 15.6 Hz, 
S20 
1H), 5.79 (m, 2H), 4.18 (m, 4H), 2.30 (m, 3H), 1.26 (m, 17H), 0.87 (t, J = 6.8 Hz, 3H) . 
13C NMR (101 MHz, CDCl3), δ: 166.4, 166.3, 151.4, 146.0, 123.1, 121.7, 60.3, 60.2, 
41.6, 36.9, 33.9, 31.8, 29.5, 29.4, 29.2, 27.0, 22.6, 14.2 (2C), 14.0. 
HRMS (ESI+, m/z): calcd. for C20H35O4, [M+H+]: 339.2535; found: 339.2530. 
Enantiomeric excess was determined by chiral HPLC analysis, Chiralpak AD-H column, 




(-)-3-Allyl-4-methylenechromene (4): TBAB (2 g), TBAA (0.9 g, 3 mmol), Pd(OAc)2 
(3 mol%) and (+)-2a (366 mg, 1.37 mmol) were stirred and heated at 100 °C for 1h. 
Water (3 mL) and EtOAc (3 mL) were added and, after cooling to r.t., the organic phase 
separated. The aqueous phase was extracted with EtOAc (2 x 5 mL). The combined 
organic phases were dried over Na2SO4 and concentrated under reduced pressure to yield 
the crude product which was purified by flash chromatography (SiO2, EtOAc/Pentane 
1:99, Rf = 0.5). 78% yield, ratio exo:endo = 99:1. 1H NMR (400 MHz, CDCl3), δ: 7.47 
(dd, J = 1.6, 7.7 Hz, 1H), 7.09 (dt, J = 1.6, 7.7 Hz, 1H), 6.81 (dt, J = 1.3, 7.5 Hz, 1H), 
6.76 (dd, J = 1.0, 8.2 Hz, 1H), 5.76 (m, 1H), 5.44 (s, 1H), 5.02 (m, 1H), 4.98 (m, 1H), 
4.82 (s, 1H), 4.08 (d, J = 3.5 Hz, 2H), 2.49 (m, 1H), 2.23 (m, 2H). 13C NMR (101 MHz, 
CDCl3), δ: 153.9, 140.6, 135.9, 129.4, 124.9, 120.9, 120.8, 117.1, 116.9, 106.9, 69.2, 
40.2, 34.9. 
[α]D20 = -44 (c = 1.0, CHCl3). 
HRMS (ESI+, m/z): calcd. for C13H15O, [M+H+]: 187.1123; found: 187.1117. 
 
 
2-(4-Oxochroman-3-yl)acetaldehyde (5): Dried ozone gas was passed through a 
colorless solution of 4 (112 mg) in CH2Cl2 (5 mL) at -78 °C for 20 min until the resulting 
S21 
solution became blue-white. After addition of CH2Cl2 (8 mL), nitrogen gas was passed 
through at -78 °C until the resulting solution became colorless. Dimethyl sulfide (1 mL) 
was added at -78 °C, and the resulting solution was stirred at 0 °C for 10 min, and at 
room temperature for 18 h. The whole was mixed with CH2Cl2 (8 mL) and water (15 
mL), and the aqueous layer was extracted with CH2Cl2 (20 mL) twice. The organic 
extracts were combined, washed with brine (20 mL), dried over Na2SO4, and evaporated 
to dryness. The residue was subjected to column chromatography (SiO2, EtOAc/Pentane 
5:95) affording 5 (81% yield) as a colorless oil. 1H NMR (400 MHz, CDCl3), δ: 9.86 (s, 
1H), 7.86 (dd, J = 1.6, 7.9 Hz, 1H), 7.47 (t, J = 7.8 Hz, 1H), 7.01 (t, J = 7.5 Hz, 1H), 6.96 
(d, J = 8.3 Hz, 1H), 4.54 (dd, J = 5.4, 11.1 Hz, 1H), 4.22 (t, J = 11.5 Hz, 1H), 3.43 (m, 
1H), 3.06 (dd, J = 5.1, 18.3 Hz, 1H), 2.53 (dd, J = 7.2, 18.3 Hz, 1H). 13C NMR (101 
MHz, CDCl3), δ: 198.8, 192.7, 161.7, 136.1, 127.3, 121.5, 120.4, 117.8, 70.1, 40.7, 39.4. 
HRMS (ESI+, m/z): calcd. for C11H11O3, [M+H+]: 191.0708; found: 191.0703. 
 
 
(+)-1-Benzyl-1,2,3,3a,4,9b-hexahydrochromeno[4,3-b]pyrrole (6): To a solution of 
aldehyde 5 (23 mg, 0.12 mmol) in MeOH (3 mL) were added sequentially benzylamine 
hydrochloride (95.1mg, 0.66 mmol) and then NaBH3CN (7 mg, 0.11 mmol). After 
stirring for 30 min, an additional portion of NaBH3CN (7 mg, 0.11 mmol) was added and 
stirring was continued for 1 h. A third portion of NaBH3CN (21 mg, 0.33 mmol) was then 
added, and stirring was continued overnight. After removing the MeOH, CH2Cl2 was 
added and the resulting organic solution was washed with sat. aq. NaHCO3 solution, 
dried and concentrated. The resulting mixture was purified by column chromatography 
(SiO2, EtOAc/Pentane 10:90) afforded 6 (95% yield, 96:4 e.r.) as a waxy solid. 1H NMR 
(400 MHz, CDCl3), δ: 7.24 (m, 7H), 6.92 (m, 2H), 4.41 (d, J = 12.7 Hz, 1H), 4.07 (m, 
2H), 3.23 (m, 2H), 2.88 (dt, J = 2.8, 9.1 Hz, 1H), 2.45 (m, 1H), 2.18 (c, J = 8.9 Hz, 1H), 
2.03 (m, 1H), 1.40 (m, 1H). 13C NMR (101 MHz, CDCl3), δ: 155.4, 139.9, 132.0, 128.8, 
128.5 (2C), 128.0 (2C), 126.7, 121.5, 119.7, 116.8, 67.6, 61.4, 57.3, 51.2, 34.4, 24.4. 
S22 
[α]D20 = +96 (c = 1.0, CHCl3). 
HRMS (ESI+, m/z): calcd. for C18H20NO, [M+H+]: 266.1545; found: 266.1539. 
Enantiomeric excess was determined by chiral HPLC analysis, Chiralcel OJ-H column, 
n-heptane/i-PrOH 99:1, 40 °C, 225 nm, retention times (min): 17.4 (major) and 20.7 
(minor). 
S23 
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7. Representative HPLC traces: 
 
(‐)‐2a
rac‐2a
S52
(+)‐2b
rac‐2b
S53
Mixture of
(‐)‐2c and (+)‐2c
(+)‐2c
S54
(‐)‐2d
(+)‐2d
S55
(‐)‐2e
(+)‐2e
S56
N
Ts
Br
rac‐2f
(‐)‐2f
S57
(+)‐2g
Mixture of (+)‐
2g and (‐)‐2g
S58
(+)‐2h
(‐)‐2h and 10% (+)‐2h
S59
N
Ts
(+)‐2i
Mixture of (+)‐
2i and (‐)‐2i
S60
(+)‐2j
rac‐2j
S61
(+) ‐2k
(‐)‐2k
S62
(‐)‐2l
(+)‐2l
S63
Mixture of (+)‐
7m and (‐)‐7m
(+)‐7m
S64
syn anti
linear
syn anti
linear
(+)‐7m
Diasteromeric
mixture‐7m
S65
Mixture of (+)‐7o 
and (‐)‐7o
(+)‐7o
S66
(+)‐7p
(‐)‐7p
S67
Mixture of (+) and
(‐)‐6
(+)‐6
S68
